Press release
Datamonitor Healthcare Parkinson's Disease KOL Interviews
March 16, 2017
Datamonitor Healthcare interviewed two neurologists, one based in Italy and the other in the US, to gauge their prescribing habits and views on current treatment options and challenges, late-stage clinical candidates and pricing and reimbursement considerations for Parkinson’s disease. The drugs discussed are listed below. The two interviews were combined into a single report.
For a Detailed description and table of contents of this report please click here: https://www.reportsworldwide.com/report/datamonitor-healthcare-parkinsons-disease-kol-interviews
APL-130277, Apokyn (STDAF), Aricept (ESALY), Azilect (TEVA), Clozaril (NVS), Comtan (NVS), CVT-301 (ACOR), Duopa (ABBV), Exelon (NVS), Mirapex, Namenda (AGN), ND0612H (NDRM), ND0612L (NDRM), Neupro, Northera (HLUKF), Nouriast, Nuplazid (ACAD), Ongentys (NBIX), preladenant (MRK), Requip IR (GSK), Rytary (IPXL), Seroquel (AZN), Symmetrel (ENDP), Tasmar (MYL), tozadenant (ACOR), Xadago, Zonegran (CXRX)."
To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41335
About ReportsWorldwide.com
ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.
Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Datamonitor Healthcare Parkinson's Disease KOL Interviews here
News-ID: 658631 • Views: …
More Releases from ReportsWorldwide
World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence…
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports.
Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors.
Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that…
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports.
This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers:
• CommScope/Airvana
• Comba Telecom
• Ericsson
• Huawei Technologies
• Nokia
• SpiderCloud
• ZTE Corporation
This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021.
To view a detailed description and Table of…
More Releases for Datamonitor
Datamonitor Healthcare Osteoporosis KOL Interviews
ReportsWorldwide has announced the addition of a new report title Datamonitor Healthcare Osteoporosis KOL Interviews to its growing collection of premium market research reports.
For a Detailed description and table of contents of this report please click here: https://www.reportsworldwide.com/report/datamonitor-healthcare-osteoporosis-kol-interviews
February 03, 2017
Datamonitor Healthcare interviewed an endocrinologist based in the US and a rheumatologist based in the UK to gauge their views on current treatment options, late stage clinical candidates, treatment challenges…
Datamonitor Healthcare Crohn's Disease KOL Interviews
ReportsWorldwide has announced the addition of a new report title Datamonitor Healthcare Crohn's Disease KOL Interviews to its growing collection of premium market research reports.
April 05, 2017
Datamonitor Healthcare interviewed two inflammatory bowel disease experts, one based in France and the other in Italy, to gauge their views on marketed drugs for Crohn’s disease (CD), late-stage clinical candidates, treatment challenges and unmet needs and the future treatment of CD. The drugs…
Datamonitor: Greece - pharmaceutical companies take a stand over pricing
Following the publication of a new pricing bulletin which aims to cut healthcare costs in Greece, a significant proportion of pharmaceutical companies currently operating in the country have challenged the new prices. While there are many ways in which companies can beat the new pricing laws, the regulations may prove harmful to pharmaceutical company sales in Greece and, indeed, across Europe.
The battle continues to rage between pharmaceutical companies and the…
Datamonitor: ATS 2010 - developments in IPF and cystic fibrosis
The FDA's recent refusal of Esbriet and the publication of new guidelines for the treatment of idiopathic pulmonary fibrosis drove considerable interest in this disease at the 2010 meeting of the American Thoracic Society. Furthermore, the approval of the first new inhaled antibiotic for cystic fibrosis in over a decade brought renewed focus on this rare but extremely debilitating disease.
Idiopathic pulmonary fibrosis (IPF) is an often fatal form of interstitial…
Datamonitor: Commercial Insight - Antihormonal Cancer Therapies on reports-resea …
Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about $6.9 billion in the seven major pharmaceutical markets in 2008.
Research and analysis highlights
The antihormonals market was worth $6.9 billion in 2008 across the seven major…
Datamonitor: Commercial Insight - Cytotoxic Therapies on reports-research.com
Despite the advent of molecular targeted therapies, cytotoxic chemotherapy remains the cornerstone of cancer treatment and is used across nearly the entire spectrum of tumor types. A number of cytotoxic drugs are on the market, however only a few currently dominate in terms of revenues, with Taxotere (docetaxel; Sanofi-Aventis), Eloxatin (oxaliplatin; Sanofi-Aventis) and Gemzar (gemcitabine; Eli Lilly) the three leading cytotoxics in terms of sales in 2008, with 7MM annual…
